According to Zacks, “Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in developing and commercializing a novel class of therapeutics primarily in the United States. The companys lead product includes ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers which are in clinical stage. Aileron Therapeutics, Inc. is based in Cambridge, Massachusetts. “
ALRN has been the topic of a number of other research reports. William Blair reissued an outperform rating on shares of Aileron Therapeutics in a research note on Monday, May 6th. HC Wainwright lowered their price target on shares of Conatus Pharmaceuticals from $14.00 to $8.00 and set a buy rating for the company in a report on Monday, March 11th. Finally, Canaccord Genuity raised shares of Nuvista Energy to a buy rating in a report on Tuesday, April 9th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $4.33.
Aileron Therapeutics (NASDAQ:ALRN) last issued its earnings results on Wednesday, May 8th. The company reported ($0.49) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.13). Equities research analysts expect that Aileron Therapeutics will post -1.11 EPS for the current fiscal year.
An institutional investor recently raised its position in Aileron Therapeutics stock. Jennison Associates LLC grew its stake in shares of Aileron Therapeutics Inc (NASDAQ:ALRN) by 649.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,040,255 shares of the company’s stock after acquiring an additional 1,768,073 shares during the period. Jennison Associates LLC owned about 13.72% of Aileron Therapeutics worth $3,828,000 at the end of the most recent quarter. 29.17% of the stock is owned by hedge funds and other institutional investors.
Aileron Therapeutics Company Profile
Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.
Recommended Story: How much can an individual set aside as a catch-up contribution?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.